Essential Healthcare News
SEE OTHER BRANDS

Global take on healthcare and wellness news

Essential Healthcare News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Essential Healthcare News.

Press releases published on April 30, 2025

Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard  - Au congrès annuel de l’AACR 2025

Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard - Au congrès annuel de l’AACR 2025

Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard Au congrès annuel de l’AACR 2025 Une nouvelle signature d’expression génique pour prédire la réponse clinique aux points de contrôle immunitaires …

Nicox Provides Full Year 2024 Financial Results

Nicox Provides Full Year 2024 Financial Results

Nicox SA revenue of €7.9 million for full year 2024  Exceptional income of €13.7 million following the transfer of VYZULTA’s future revenue stream to Soleus Capital Nicox SA cash of €10.5 million on 31 December 2024 and the Company estimates it is …

Nicox : Résultats financiers de l’année 2024

Nicox : Résultats financiers de l’année 2024

Chiffre d’affaires de Nicox SA de 7,9 millions d’euros pour l’année 2024  Produits exceptionnels de 13,7 millions d’euros suite à la cession du flux futur de redevances de VYZULTA au fond Soleus Capital Trésorerie de Nicox SA au 31 décembre 2024 de 10,5 …

Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO

Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO

Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO New recruits expand senior team capabilities as the business progresses its lead HDAC6 inhibitor program, AGT-100216, into the clinic for the …

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for …

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million  up by 3% in constant currencies (cc); stable in USD up by 5%[1] at a comparable growth rate (CGR), when adjusted for impact of …

Basel Medical Group Completes Acquisition of Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia 

Basel Medical Group Completes Acquisition of Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia 

Singapore , April 30, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL), today announced the closing of the acquisition of Bethesda Medical Pte. Ltd., a leading Singapore-based healthcare provider specializing in diagnostic imaging and …

Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel

Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel

VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to …

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service